The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

The New Jersey Law Journal has reported that the New Jersey Municipal Employee Benefits Fund has filed a class action lawsuit against Johnson & Johnson subsidiary DePuy Orthopaedics stemming from the problems with the DePuy ASR hip replacement systems.

Published reports have shown that Johnson & Johnson and DePuy knew about the artificial hip defect for years, but failed to correct the problem or warn patients. In fact, DePuy paid orthopedic surgeons $80 million to promote the defective hips.

What You Need To Know About Johnson & Johnson’s DePuy Artificial Hip Recall

DePuy began manufacturing the ASR hips in 2003 and they were approved for use in 2005. By 2007, DePuy knew that its ASR artificial hips were defective. Patients receiving the defective hips have reported a greater amount of pain and need for revision surgeries (removal of the artificial hip and replacement with another implant).

DePuy Hip Recall: Frequently Asked Questions (FAQ)

Patients who may have received a defective hip should get more information about the DePuy hip recall and potential dangers.

[More information on the DePuy Hip Recall]

[More information on Johnson & Johnson’s many recent recalls]

(c) Copyright 2011 Brett A. Emison

There are certain systems indicating problems with an artificial hip. These symptoms include:

  • Serious / Chronic Pain
  • Inflammation
  • Loosening of the Implant, with Possible Detachment
  • Dislocation of the Hip Implant
  • Fracture of the Bone Around the Hip Implant

In addition, there are reports of cancer risks associated with the DePuy hip recall. The ASR hips recalled by DePuy can potentially release toxic, perhaps cancer-causing, metal shavings into the tissue surrounding the defective artificial hip and be spread throughout the body through the bloodstream.

Comments for this article are closed.